deferasirox (AST-0509) / Austhera Biosci - LARVOL DELTA

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation (clinicaltrials.gov) - P2 | N=25 | Completed | Sponsor: DisperSol Technologies, LLC | Recruiting ➔ Completed | N=36 ➔ 25 | Trial primary completion date: Sep 2021 ➔ Jun 2021

Enrollment change • Trial completion • Trial primary completion date • Beta-Thalassemia • Genetic Disorders • MRI

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation (clinicaltrials.gov) - P2; N=36; Recruiting; Sponsor: DisperSol Technologies, LLC; Trial completion date: Mar 2021 ➔ Oct 2021; Trial primary completion date: Feb 2021 ➔ Sep 2021

Trial completion date • Trial primary completion date • Beta-Thalassemia • Genetic Disorders

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation (clinicaltrials.gov) - P2; N=36; Recruiting; Sponsor: DisperSol Technologies, LLC; Trial completion date: Dec 2020 ➔ Mar 2021; Trial primary completion date: Jul 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date • Beta-Thalassemia • Genetic Disorders

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation (clinicaltrials.gov) - P2; N=36; Recruiting; Sponsor: DisperSol Technologies, LLC; Trial completion date: Dec 2019 ➔ Dec 2020; Trial primary completion date: Jul 2019 ➔ Jul 2020

Clinical • Trial completion date • Trial primary completion date

A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major (Dovepress) - P=NA, N=40; "The addition of amlodipine to the standard chelation therapy in transfusion-dependent thalassemia major patients improves myocardial iron overload without increasing the adverse effects."

Clinical data